BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 25524580)

  • 1. Plasmacytoid dendritic cells, a role in neoplastic prevention and progression.
    Lombardi VC; Khaiboullina SF; Rizvanov AA
    Eur J Clin Invest; 2015 Jan; 45 Suppl 1():1-8. PubMed ID: 25524580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New perspective in immunotherapy: local imiquimod treatment].
    Kemény L; Nagy N
    Orv Hetil; 2010 May; 151(19):774-83. PubMed ID: 20427260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment.
    Urosevic M; Dummer R; Conrad C; Beyeler M; Laine E; Burg G; Gilliet M
    J Natl Cancer Inst; 2005 Aug; 97(15):1143-53. PubMed ID: 16077073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasmacytoid dendritic cell in immunity and cancer.
    Mitchell D; Chintala S; Dey M
    J Neuroimmunol; 2018 Sep; 322():63-73. PubMed ID: 30049538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells.
    Drobits B; Holcmann M; Amberg N; Swiecki M; Grundtner R; Hammer M; Colonna M; Sibilia M
    J Clin Invest; 2012 Feb; 122(2):575-85. PubMed ID: 22251703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasmacytoid dendritic cells support melanoma progression by promoting Th2 and regulatory immunity through OX40L and ICOSL.
    Aspord C; Leccia MT; Charles J; Plumas J
    Cancer Immunol Res; 2013 Dec; 1(6):402-15. PubMed ID: 24778133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasmacytoid dendritic cell role in cutaneous malignancies.
    Saadeh D; Kurban M; Abbas O
    J Dermatol Sci; 2016 Jul; 83(1):3-9. PubMed ID: 27236509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor microenvironment converts plasmacytoid dendritic cells into immunosuppressive/tolerogenic cells: insight into the molecular mechanisms.
    Demoulin S; Herfs M; Delvenne P; Hubert P
    J Leukoc Biol; 2013 Mar; 93(3):343-52. PubMed ID: 23136258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic cell immunotherapy for the treatment of neoplastic disease.
    Decker WK; Xing D; Shpall EJ
    Biol Blood Marrow Transplant; 2006 Feb; 12(2):113-25. PubMed ID: 16443510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-α-mediated antitumor reactivity.
    Kalb ML; Glaser A; Stary G; Koszik F; Stingl G
    J Immunol; 2012 Feb; 188(4):1583-91. PubMed ID: 22231699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists.
    Rajagopal D; Paturel C; Morel Y; Uematsu S; Akira S; Diebold SS
    Blood; 2010 Mar; 115(10):1949-57. PubMed ID: 20065291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo cancer vaccination: Which dendritic cells to target and how?
    Chiang CL; Kandalaft LE
    Cancer Treat Rev; 2018 Dec; 71():88-101. PubMed ID: 30390423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours.
    Conroy H; Marshall NA; Mills KH
    Oncogene; 2008 Jan; 27(2):168-80. PubMed ID: 18176598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TLR-activated plasmacytoid dendritic cells inhibit breast cancer cell growth in vitro and in vivo.
    Wu J; Li S; Yang Y; Zhu S; Zhang M; Qiao Y; Liu YJ; Chen J
    Oncotarget; 2017 Feb; 8(7):11708-11718. PubMed ID: 28052019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral CpG-B Promotes Antitumoral Neutrophil, cDC, and T-cell Cooperation without Reprograming Tolerogenic pDC.
    Humbert M; Guery L; Brighouse D; Lemeille S; Hugues S
    Cancer Res; 2018 Jun; 78(12):3280-3292. PubMed ID: 29588348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TLR7 ligand augments GM-CSF-initiated antitumor immunity through activation of plasmacytoid dendritic cells.
    Narusawa M; Inoue H; Sakamoto C; Matsumura Y; Takahashi A; Inoue T; Watanabe A; Miyamoto S; Miura Y; Hijikata Y; Tanaka Y; Inoue M; Takayama K; Okazaki T; Hasegawa M; Nakanishi Y; Tani K
    Cancer Immunol Res; 2014 Jun; 2(6):568-80. PubMed ID: 24830413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cells from bench to bedside and back.
    Adema GJ
    Immunol Lett; 2009 Feb; 122(2):128-30. PubMed ID: 19121337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined cytotoxic activity of an infectious, but non-replicative herpes simplex virus type 1 and plasmacytoid dendritic cells against tumour cells.
    Thomann S; Boscheinen JB; Vogel K; Knipe DM; DeLuca N; Gross S; Schuler-Thurner B; Schuster P; Schmidt B
    Immunology; 2015 Oct; 146(2):327-38. PubMed ID: 26194553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human Plasmacytoid Dendritic Cells and Cutaneous Melanoma.
    Monti M; Consoli F; Vescovi R; Bugatti M; Vermi W
    Cells; 2020 Feb; 9(2):. PubMed ID: 32054102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HMGB1 secretion during cervical carcinogenesis promotes the acquisition of a tolerogenic functionality by plasmacytoid dendritic cells.
    Demoulin S; Herfs M; Somja J; Roncarati P; Delvenne P; Hubert P
    Int J Cancer; 2015 Jul; 137(2):345-58. PubMed ID: 25492101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.